While the PLCO Cancer Screening trial demonstrated no observed mortality benefit associated with screening for prostate cancer with prostate-specific antigen and rectal exam, the knowledge gained about prostate cancer and screening and resources developed in completing the trial make the trial a success.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Grubb RL, Pinsky P, Prorok PC, Andriole GL. Are you the author?
Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA; Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
Reference: Eur Urol. 2015 May 7. pii: S0302-2838(15)00328-0.